Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Q3 Revenues Decline 31 Percent as Net Loss Nearly Doubles

NEW YORK, Nov. 2 (GenomeWeb News) - Ciphergen Biosystems yesterday reported a 31-percent decline in third-quarter revenue and almost doubled losses as sales of its ProteinChip mass spectrometry systems and BioSepra process chromatography products took a hit.

 

Revenues for the quarter ended Sept. 30 totaled $11 million, down from $16 million during the same period last year.

 

R&D expenses declined to $4.7 million from $5.4 million during the year-ago quarter.

 

Ciphergen's loss for the quarter widened to $9.5 million, or $.33 per share, almost twice as much as last year's loss of $5.2 million, or $.18 per share, during the third quarter.

 

As of Sept. 30, Ciphergen had $19 million in cash, cash equivalents, and investments in securities.


Last week, the company said it will sell its BioSepra business to Pall for $32 million.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.